Addressing questions about the HPV vaccine project in India

The Lancet Oncology

Volumn 14, Issue 12, 2013, Pages

  LaMontagne, D Scott ^a   Sherris, Jacqueline D ^b  

^a Program for Appropriate Technology in Health   (United States)

^b Public Health Impact   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; INDIA; LETTER; MEDICAL RESEARCH; PAPILLOMAVIRUS INFECTION; PERU; PRIORITY JOURNAL; UGANDA; UTERINE CERVIX CANCER; VIET NAM; WART VIRUS;

DELIVERY OF HEALTH CARE; HUMANS; NEOPLASMS; PALLIATIVE CARE;

EID: 84886645636     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70476-5     Document Type: Letter

References (5)

1. Sharma DC Rights violation found in HPV vaccine studies in India. Lancet Oncol 2013, 14:e443.
2. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011, 89:821. 30B.
3. Global Advisory Committee on Vaccine Safety, 12-13 June 2013. Wkly Epidemiol Rec 2013, 88:301-312. WHO.
4. Schiller JT, Castellsagué X, Garland SM A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30:F123-F138.
5. Interim Report of the Committee appointed by the Govt. of India, no V.25011/160/2010-HR, 15th April, 2010, to enquire into "Alleged irregularities in the conduct of studies using Human Papilloma Virus (HPV) vaccine" by PATH in India, November 9th, 2010.